Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Interstitial Cystitis
Interventions: Dexmedetomidine, Normal Saline; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions: PANDA-VAC, Pembrolizumab; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cardiac Surgery-CABG, Cardiac Valve Replacement
Interventions: Epogen, Normal Saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postural Tachycardia Syndrome
Interventions: Losartan, Ascorbic Acid (Vitamin C), Normal Saline; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 14 Years to 29 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Femur Fracture
Interventions: 0.5% ropivacaine, Normal Saline; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Ebola Hemorrhagic Fever
Interventions: AVI-7537, Normal Saline Solution (NSS); Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Septic Shock
Interventions: Vitamin C, Normal saline; Drug
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Saline, Insulin detemir, Insulin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 89 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Tacoma, Washington

Conditions: Dental Pain
Interventions: Bupivacaine liposome, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: AG-920; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Arthroscopic Knee Surgery
Interventions: Hyperosmolar Saline, Normal saline; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Glenohumeral Osteoarthritis
Interventions: ZILRETTA, Placebo; Drug · Other
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 32
States / cities: Vestavia Hills, Alabama • Surprise, Arizona • Tucson, Arizona + 29 more

Conditions: Healthy
Interventions: Endotoxin, Placebo; Biological · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Romidepsin, Placebo for Romidepsin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Patent Ductus Arteriosus (PDA), Acute Kidney Injury (AKI)
Interventions: Fenoldopam, 0.9%NS; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 0 Days to 28 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: End Stage Renal Disease, Chronic Kidney Diseases
Interventions: Berinert, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant), Clostridium difficile toxoids A and B (high-dose without adjuvant), Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Redding, California • Bristol, Connecticut • Stamford, Connecticut + 25 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Synthetic human AG, Arginine, 0.9% saline solution; Drug
Lead sponsor: Jenny Tong, MD, MPH; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: GLYX-13, IV normal saline; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Infertility, Infertility, Female, Infertility, Male
Interventions: Saline Solution for Injection, Leuprolide Acetate; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Achondroplasia
Interventions: BMN 111, Normal Saline; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Varespladib, Placebo (Normal Saline); Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 5 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Pain
Interventions: IV acetaminophen, IV placebo, hydromorphone; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 64 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Tissue Plasminogen Activator, Intraventricular Brain Hemorrhage
Interventions: Tissue Plasminogen Activator (tPA), Isotonic solution; Drug · Procedure
Lead sponsor: David Dornbos; Other
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

Local Vasoconstriction in Postural Tachycardia Syndrome

Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Hyperosmolar Saline Irrigation Fluid in Arthroscopic Knee Surgery

ZILRETTA in Subjects With Shoulder Osteoarthritis

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Berinert (C1INH) vs Placebo for DGF/IRI

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Ghrelin and Beta Cell Function in Diabetes

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

GnRH Agonist at Embryo Transfer: IVF Outcomes

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients

CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance